Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Pavlidis
N
N
Department of Medical Oncology, University of Ioannina, Greece.
Briasoulis
E
E
Pentheroudakis
G
G
D004358:Drug Therapy; D004359:Drug Therapy, Combination; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053554:Keratin-20 / Q000378:metabolism; D053552:Keratin-7 / Q000378:metabolism; D008207:Lymphatic Metastasis; D008297:Male; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis* / Q000628:therapy*; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D053554:Keratin-20; D053552:Keratin-7; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017430:Prostate-Specific Antigen